Genetic Technologies Ltd. (GENE)
Stock Price:
$4.08 USD
-0.09 (-2.16%)
Updated Aug 3, 2020 4:00 PM EDT - Market closed
After-hours: $4.09 +0.01 (0.25%) Aug 3, 6:35 PM
Key Info
| Market Cap |
56.18M |
| Revenue (ttm) |
17,918 |
| Net Income (ttm) |
-4.53M |
| Shares Out |
13.77M |
| EPS (ttm) |
-0.30 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 3, 2020 |
| Last Price |
$4.08 |
| Previous Close |
$4.17 |
| Change ($) |
-0.09 |
| Change (%) |
-2.16% |
| Day's Open |
4.16 |
| Day's Range |
3.98 - 4.16 |
| Day's Volume |
837,952 |
| 52-Week Range |
1.41 - 10.30 |
More Stats
| Market Cap |
56.18M |
| Enterprise Value |
54.68M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
13.77M |
| Float |
6.14M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.30 |
| FCF / Share |
-0.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
79,966 |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
1.25 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
3,135.33 |
| PB Ratio |
27.97 |
| Revenue |
17,918 |
| Operating Income |
-4.94M |
| Net Income |
-4.53M |
| Free Cash Flow |
-4.31M |
| Net Cash |
1.50M |
| Net Cash / Share |
0.11 |
| Gross Margin |
-985.78% |
| Operating Margin |
-27,581.59% |
| Profit Margin |
-25,253.90% |
| FCF Margin |
-24,066.54% |
| ROA |
-96.72% |
| ROE |
-202.34% |
| ROIC |
1,132.20% |
Key stats in USD, based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
25.7
Current: $4.08
High
25.7
Target: 25.65
*Average 12-month USD price target from 1 stock analysts.
Financial Performance
Financial numbers in millions AUD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 0.03 | 0.19 | 0.52 | 1.13 | 3.04 | 5.43 | 8.16 | 6.83 | 18.48 | 8.66 |
| Revenue Growth | -86.56% | -63.5% | -53.92% | -62.98% | -44.01% | -33.5% | 19.55% | -63.05% | 113.46% | - |
| Gross Profit | -0.25 | -0.11 | 0.03 | 0.38 | 2.15 | 3.59 | 6.22 | 4.88 | 16.44 | 5.93 |
| Operating Income | -7.02 | -6.40 | -8.72 | -8.92 | -9.87 | -10.21 | -9.33 | -10.41 | 1.25 | -10.13 |
| Net Income | -6.43 | -5.46 | -8.40 | -8.46 | -8.81 | -10.13 | -9.35 | -5.30 | 0.90 | -9.36 |
| Shares Outstanding | 2,635 | 2,435 | 2,122 | 429 | 268 | 144 | 118 | 20.23 | 20.23 | 18.73 |
| Earnings Per Share | -0.04 | -0.03 | -0.06 | -0.29 | -0.49 | -1.06 | -1.18 | -3.45 | 0.66 | -7.38 |
| Operating Cash Flow | -6.07 | -5.64 | -6.85 | -7.73 | -9.69 | -10.99 | -7.52 | -7.67 | 2.23 | -4.30 |
| Capital Expenditures | -0.05 | - | -0.18 | -0.30 | -0.14 | -0.05 | -0.05 | -0.04 | 0.01 | -0.14 |
| Free Cash Flow | -6.12 | -5.64 | -7.03 | -8.02 | -9.83 | -11.04 | -7.57 | -7.72 | 2.24 | -4.44 |
| Cash & Equivalents | 2.13 | 5.49 | 10.99 | 11.18 | 18.34 | 2.83 | 1.72 | 8.90 | 5.10 | 3.31 |
| Total Debt | - | - | - | - | - | - | - | 0.02 | 0.07 | 0.38 |
| Net Cash / Debt | 2.13 | 5.49 | 10.99 | 11.18 | 18.34 | 2.83 | 1.72 | 8.88 | 5.04 | 2.92 |
| Assets | 3.27 | 6.17 | 12.11 | 13.29 | 20.72 | 6.73 | 8.32 | 16.44 | 8.92 | 8.28 |
| Liabilities | 1.49 | 1.45 | 1.53 | 1.41 | 1.76 | 4.90 | 2.56 | 2.04 | 2.11 | 2.56 |
| Book Value | 1.77 | 4.71 | 10.58 | 11.88 | 18.96 | 1.83 | 5.64 | 14.25 | 6.61 | 5.72 |
Numbers in millions AUD, except per-share numbers.
Company Details
| Full Name |
Genetic Technologies Ltd. |
| CEO |
Jerzy Muchnicki |
Stock Information
| Ticker Symbol |
GENE |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Diagnostics & Research |
| Unique Identifier |
NASDAQ: GENE |
Description
Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company also engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. In addition, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.